The acquisition expands Takeda’s immuno-oncology and innate immune cell therapy portfolio with novel platforms leveraging T cells for the potential treatment of solid tumours and haematological malignancies
The combined entity will have 12 hospitals with 3,666 beds
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
The company operates four mid-sized hospitals with a total bed capacity of 556 in eastern India
The revised deal involves a cash consideration only as against the earlier proposal of cash and equity
Equity raise to finance growth and investments in the biological space
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials
Since its inception, the company has either acquired or taken a majority stake in five companies
Subscribe To Our Newsletter & Stay Updated
